Alltrna Funding, Investors & Competitors

Alltrna has raised $159M across 2 funding rounds, most recently a $109M Series B in August 2023.

Last Alltrna funding round

$109M

Series B · Aug 2023

Cumulative funding Alltrna raised

$159M

across 2 funding rounds

Key investors in Alltrna

  • Flagship Pioneering

Alltrna Overview

About Alltrna

Altrna is a Boston-headquartered biotechnology firm pioneering tRNA therapeutics derived from its proprietary platform. It deciphers tRNA biology to modulate mRNA translation into proteins, addressing genetic diseases through programmable tRNA molecules. Incorporating AI and machine learning, the platform designs therapeutics for oncology, rare diseases, and neurodegeneration. Altrna collaborates with academic institutions like MIT and Broad Institute on preclinical studies.


Founded

2018

HQ

United StatesUnited States

Status

Privately held

Customer focus

B2B

Revenue model

Product sales, Subscription

Alltrna Funding History

Alltrna has raised a total of $159M across 2 funding rounds.

Alltrna's first fundraising round was a $50M undisclosed-stage round in November 2021. The most recent completed round was a $109M Series B in August 2023.

Alltrna funding rounds

Alltrna funding rounds
DateStageInvestorsRaisedDeal Summary
Aug 2023Series BFlagship Pioneering (lead)$109MAlltrna is a Flagship Pioneering company founded in 2018 that unlocks transfer RNA (tRNA) biology to design programmable tRNA therapeutics addressing thousands of rare and common diseases driven by shared genetic mutations, particularly Stop Codon Diseases like cystic fibrosis, Duchenne muscular dystrophy, beta thalassemia, and cancers. The platform uses AI/ML to optimize tRNA sequences and modifications for protein production regulation. Alltrna was initially launched with $50 million from Flagship Pioneering. On August 9, 2023, Alltrna raised $109 million in a Series B financing led by founder Flagship Pioneering, with participation from top-tier investors, to advance its platform and first drug candidates toward the clinic for an initial indication in Stop Codon Disease. The funds will accelerate machine learning-driven tRNA development and candidate progression. The company is led by an all-women executive team, with Michelle Werner as CEO and CEO-Partner at Flagship Pioneering. Alltrna's approach focuses on creating a single tRNA medicine to unify treatment across diseases with premature termination codon (PTC) mutations, restoring disrupted protein production. Prior to the Series B, Alltrna formed a scientific advisory board with leading RNA experts and engineered improved tRNA oligonucleotides for in vivo readthrough of PTCs, as announced in May 2023.
Nov 2021Undisclosed stageFlagship Pioneering (lead)$50MAlltrna is a Flagship Pioneering company founded in 2018 that unlocks transfer RNA (tRNA) biology to develop tRNA medicines for treating thousands of genetic diseases, including rare, ultrarare, and common conditions driven by shared mutations, using a platform that incorporates AI/ML tools to design programmable tRNA therapeutics. Flagship Pioneering launched Alltrna publicly on November 9, 2021, with an initial commitment of $50 million in committed capital following three years of in-house platform development at Flagship Labs. The company aims to use a single tRNA medicine to address multiple diseases by regulating the protein universe, though no specific diseases or human trials were disclosed at launch. Co-founded by Lovisa Afzelius, Ph.D., who serves as CEO and previously worked at Repertoire Immune Medicines, Pfizer, and AstraZeneca, Alltrna had a team of about 30 people at launch, including key hires like Nikolai Naryshkin, Ph.D., SVP of therapeutic platform and pipeline strategy from PTC Therapeutics, and William Kiesman as SVP of chemistry, manufacturing and controls from Biogen. The $50 million infusion supports engineering tRNAs as drugs to intervene in protein translation, with potential applications in areas like cell proliferation for cancer. This launch positions Alltrna within Flagship's RNA-focused portfolio, building on successes like Moderna, amid a wave of tRNA interest seen in competitors like ReCode Therapeutics, Shape Therapeutics, and Tevard Biosciences. Subsequent developments include a $109 million Series B in August 2023 led by Flagship Pioneering with additional top-tier investors to advance the platform and first drug candidates toward clinic for Stop Codon Disease.

Who has invested in Alltrna?

1 investor has backed Alltrna across its funding rounds, including Flagship Pioneering.

Lead investors include Flagship Pioneering.


Alltrna Investors

Investors in Alltrna by funding rounds participated
InvestorHQRoundsRoleFirst check

This data is available for Pro users. Sign up to see all 1 Alltrna investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Alltrna Competitors

Alltrna competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Anthropic and OpenAI.

Public and private companies comparable to Alltrna
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
AstromechUnited StatesUnited StatesPrivate--$3.8B-
Chai DiscoveryUnited StatesSan Francisco, CAPrivate$48M-$3.8B-
AnthropicUnited StatesSan Francisco, CAPrivate$47B-$965B20.5x
OpenAIUnited StatesSan Francisco, CAPrivate$25B-$852B34.1x
SAPGermanyGermanyPublicly listed$42B$13B$248B5.4x
SnowflakeUnited StatesUnited StatesPublicly listed$4.7B($1.3B)$119B21.0x

Alltrna Public Comps

Alltrna is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B16.5x13.1x38.7x27.0x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Merck$65B$28B6.3x6.2x14.7x21.0x
Roche$77B$26B5.0x4.9x14.6x12.4x
Novartis$57B$22B5.5x5.5x14.2x13.3x
AstraZeneca$59B$19B4.8x4.5x14.6x12.7x
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x

This data is available for Pro users. Sign up to see all Alltrna competitors and their valuation data.

Start Free Trial

Common questions about Alltrna

When was Alltrna founded?Alltrna was founded in 2018.
Where is Alltrna headquartered?Alltrna is headquartered in United States.
Is Alltrna publicly listed?No, Alltrna is a private, VC-backed company.
How much funding has Alltrna raised?Alltrna has raised $159M across 2 funding rounds.
What was Alltrna's last funding round?Alltrna's last funding round was a $109M Series B in August 2023, led by Flagship Pioneering.
Who are Alltrna's investors?Alltrna's investors include Flagship Pioneering.
Which companies are comparable to Alltrna?Companies comparable to Alltrna include Astromech, Chai Discovery, Anthropic, OpenAI, SAP and Snowflake.

See companies similar to Alltrna

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial